CNDA Shopping Cart

Please leave this field blank.

Home My Account View Cart Checkout
PW53: Therapeutic Considerations for COVID-19
NW50: Chronic Fatigue Syndrome: Route to Resolution (self study)
2022 Virtual Conference: The Holistic Human: Advances in Naturopathic Primary Care
PW52: Ketamine: Therapeutic History & Current Research
NW51: Intestinal Parasites A New Approach to an Old Problem
PW50: Current Research with Psilocybin (self study)
PW51: Current Research with MDMA
NW49: Ayurvedic Medicine & Cardiology (self study)
PW49: Psychedelics & the Future of Medicine (self study)
PW48: Updates in Dermatology: Treating Hair Loss (self study)
PW52: Ketamine: Therapeutic History & Current Research
PW52: Ketamine: Therapeutic History & Current Research Storefront > Live Pharmacy Webinars

View larger image
PW52: Ketamine: Therapeutic History & Current Research
Price: $95.00
Status: Available

Please leave this field blank.

Pharmacy Webinar 52

Tues, Feb. 22, 2022
6:30pm - 8:30pm Pacific

CNDA Members (& Members of Your State Association): Use Your Coupon Code (member) At Checkout

2 CEs*
2 CEs for CA LAc (pending)

*Approved by CNDA; pending approval by OBNM

Natalie Metz, ND, MA

Ketamine is a unique psychoactive substance known for its analgesic, anesthetic, antidepressant, dissociative, and psychostimulant effects. It was synthesized in 1962, and in 1966 was developed into Ketalar, becoming the most widely used battlefield anesthetic in the Vietnam War. It is distinct in its anesthetic application as it preserves cardiovascular and respiratory function. It is a potent and complex pharmacologic agent, interacting with many receptors, and exhibiting an antagonistic effect at the NMDA receptor, effectively blocking glutamate agonism which has many physiological and phenomenological implications.

In the 1970’s ketamine gained the interest of various global therapeutic communities. It has been explored in psychotherapeutic contexts for decades since then, with early research demonstrating benefit in patients navigating problematic substance use. It is currently prescribed as an analgesic and antidepressant in primary care, and also used in the ER for depressed patients with active suicidal ideation. Ketamine is also being explored as an adjunct to psychotherapy in both psycholytic and psychedelic doses in what is known as ketamine assisted or ketamine facilitated psychotherapy.

Due to its presence in Schedule III, ketamine is the only legally available prescription psychedelic agent in the US. This both opens the door to creative explorations with on and off-label ketamine prescriptions, as well as invites a conversation about the responsibility and ethics of care associated with its use.

This is the fourth of a series of webinars which offers an overview of psychedelic-assisted therapies.

Goals and Objectives:

  • Understand basic neuroscience, pharmacology, and proposed therapeutic mechanisms of action of ketamine
  • Describe basic history of ketamine and use in therapeutic contexts
  • Demonstrate familiarity with past and current research exploring the therapeutic potentials of ketamine-assisted therapies
  • Review the outcomes of select research, demonstrating the overall safety and efficacy of ketamine-assisted therapies